of ArhGAP30 and synbindin are distinct (anti-and proproliferation), their molecular functions are both scaffold proteins that regulate protein PTM.
Interestingly, these PTM-related roles do not seem to require their canonical functions, i.e., the RhoGAP enzyme activity of ArhGAP30 and the vesicle trafficking function of synbindin. Rather, these proteins mediate the interactions of PTM kinase and client proteins by structural domains that were previously uncharacterized. Also, the functions of these scaffold proteins add to the complexity of PTM processes, as both p53 acetylation and ERK phosphorylation have been reported to be under regulation of various factors [4, 5] . It remains to be clarified which of these reported mechanisms may represent the predominant route for p53 and ERK PTMs in a specific tissue type or disease status.
The scaffold protein-mediated PTM may help to explain the prevalence of deregulated p53 and ERK PTM in cancers. As an example, ERK phosphorylation has been found in most gastric cancer tissues, but the alterations in canonical components (such as Ras, Raf and Mek) can only explain some of the abnormal ERK phosphorylation [6] . The finding that synbindin may contribute to ERK phosphorylation shed light on the multifaceted mechanisms underlying ERK hyperactivation, and indicates alternative therapeutic opportunities by targeting scaffold proteins. 
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